AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off AbbVie in 2013, Humira was the new company's cash cow. AbbVie used nearly ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy launch progresses. AbbVie (NYSE: ABBV) could be the poster child for how ...

Emerges from Chapter 11 as a Privately-Held Company under New Ownership Achieves Greatly Improved Balance Sheet and up to $100 million in Exit Financing Announces New Leadership to Support Execution ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the biotechnology sector, with a ...

NEW YORK, NY / ACCESSWIRE / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...

Eyebrows were raised when Vertex decided to exit its hepatitis C franchise last year and concentrate its efforts on cystic fibrosis (CF), but with use of its lead product Kalydeco expanding ...

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.